135049-84-2

Upstream product

• 83846-48-4 3-chloro-4-methyliodobenzene 

Downstream Products

• 279252-27-6 4-chloro-1-(2-chloro-4-iodobenzyl)-2-methylimidazole-5-carbaldehyde 
• 279252-26-5 1-(bromomethyl)-2-chloro-4-(trifluoromethyl)benzene 
• 275384-50-4 2-chloro-4-(1-pentyloxy)benzyl bromide 
• 950482-87-8 2-(2-chloro-4-iodobenzyl)-1H-isoindole-1,3-(2H)-dione 
• 950481-62-6 N-[2-chloro-4-[5-[3,5-bis(trifluoromethyl)phenyl]-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]phenylmethyl]cyclopropanecarboxamide 
• 950482-91-4 N-[(2-chloro-4-hydroxyiminomethylphenyl)methyl] cyclopropanecarboxamide 
• 950482-90-3 N-[(2-chloro-4-formylphenyl)methyl] cyclopropanecarboxamide 
• 950482-88-9 2-chloro-4-iodobenzylamine 
• 245368-22-3 3-(2-chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole 
• 219765-74-9 methyl 3-(2-chloro-4-iodobenzyl)-2-methyl-3H-imidazo[4,5-b]pyridine-5-carboxylate 
• 345635-50-9 2-chloro-4-iodobenzyl methyl sulfide 

Relevant academic research and scientific papers

2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2- yl)picolinamide derivatives of formula (I) Formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their pre

Trans olefinic glucokinase activators

2,3-Di-substituted trans olefinic N-heteroaromatic or urido propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF

Imidazole compounds represented by general formula (I): wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy inhibitory action.

DIARYL ETHER HETROCYCLES

The invention concerns a diaryl ether heterocycle of the formula I, or a pharmaceutically-acceptable salt thereof, wherein Ar1 is optionally substituted phenyl or naphthyl; X1 is oxy, thio, sulphinyl or sulphonyl; Ar2 is optionally substituted phenylene, or a 6-membered heterocyclene moiety containing up to three nitrogen atoms; Rl is (l-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(l-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and R2 and R3 together form a group of the formula ?A2?X2?A3? wherein each of A2 and A3 is (l-4C) alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino. The invention also concerns processes for the manufacture of a diaryl ether heterocycle of the formula I, or a pharmaceutically-acceptable salt thereof, and pharmaceutical compositions containing said heterocycle. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

Diaryl ether heterocycles

The invention concerns a diaryl ether heterocycle of the formula I, or a pharmaceutically-acceptable salt thereof, wherein Ar1 is optionally substituted phenyl or naphthyl;, X1 is oxy, thio, sulphinyl or sulphonyl;, Ar2 is optionally substituted phenylene, or a 6-membered heterocyclene moiety containing up to three nitrogen atoms;, R1 is (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and, R2 and R3 together form a group of the formula -A2-X2-A3- wherein each of A2 and A3 is (1-4C)alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino. The invention also concerns processes for the manufacture of a diaryl ether heterocycle of the formula I, or a pharmaceutically-acceptable salt thereof, and pharmaceutical compositions containing said heterocycle. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.